Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 7/20 | 0.51 |
| ▸ | DKK1 | O94907 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.47 |
| ▸ | CDK9 | P50750 | 8/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.47 |
| ▸ | CDK7 | P50613 | 3/20 | 0.47 |
| ▸ | CCNH | P51946 | 3/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139765 | 0.86 | IKBKB (0.47) | IKBKBDKK1GSK3BCCNT1CDK9 | |
| SCHEMBL4146248 | 0.83 | IKBKB (0.56) | IKBKBDKK1GSK3BCCNT1CDK9 | |
| SCHEMBL4144796 | 0.82 | IKBKB (0.47) | IKBKBDKK1GSK3BCCNT1CDK9 | |
| SCHEMBL3520377 | 0.80 | IKBKB (0.60) | IKBKBDKK1GSK3BCCNT1CDK9 | |
| SCHEMBL4138290 | 0.79 | CDK2 (0.46) | IKBKBDKK1GSK3BCCNT1CDK9 | |
| SCHEMBL4147159 | 0.79 | CDK9 (0.51) | IKBKBDKK1GSK3BCCNT1CDK9 | |
| SCHEMBL3516308 | 0.78 | IKBKB (0.76) | IKBKBDKK1GSK3BCCNT1CDK9 | |
| SCHEMBL3524238 | 0.77 | IKBKB (0.68) | IKBKBDKK1GSK3BCCNT1CDK9 | |
| SCHEMBL13051459 | 0.76 | IKBKB (0.56) | IKBKBDKK1GSK3BCCNT1CDK9 | |
| SCHEMBL12423171 | 0.74 | IKBKB (0.55) | IKBKBDKK1GSK3BCCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | claimed |
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | IKBKB 1593/4885DKK1 11/4885GSK3B 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.